key: cord-0833482-j2ddpc2u authors: Chinen, Yukiko; Kinjyo, Yoshino; Mekaru, Keiko; Kinjo, Tadatsugu; Higure, Yuuri; Kinjo, Takeshi; Miyagi, Kazuya; Yamada, Hisako; Masamoto, Hitoshi; Goya, Hideki; Yoshida, Tomohide; Maeshiro, Sakiko; Nakamatsu, Masashi; Fujita, Jiro; Aoki, Yoichi title: Critical respiratory failure in pregnancy complicated with COVID-19: A case report date: 2021-03-23 journal: Case Rep Womens Health DOI: 10.1016/j.crwh.2021.e00309 sha: 756a8cdcf8b0e2d3353442f8d2e3ec5102fc8e61 doc_id: 833482 cord_uid: j2ddpc2u The case is presented of a 29-year-old primiparous woman who was COVID-19-positive at 34 weeks of gestation and who developed severe acute respiratory distress syndrome. After a four-day history of fever and mild dyspnea, she was referred to hospital. Ciclesonide, dexamethasone, heparin sodium, and sulbactam/ampicillin were initiated, followed by remdesivir and tocilizumab. On the fourth day after admission (at 34 weeks 5 days of gestation), respiratory failure required ventilator management. An emergency cesarean section was performed and a 2565-g male infant was delivered with an Apgar score of 8/8 and negative COVID-19 status . However, on the following day the patient's respiratory condition deteriorated and mechanical ventilation was initiated. Subsequently, her respiratory condition quickly improved and mechanical ventilation was terminated 4 days after intubation. She was discharged 12 days after cesarean delivery. Our case provides additional evidence that raises concerns regarding the unfavorable maternal consequences of COVID-19 infection during pregnancy. Coronavirus disease-2019 (COVID-19) can cause rapid progression of viral pneumonia, leading to acute respiratory distress syndrome (ARDS) requiring intubation. In the early period of the COVID-19 pandemic, the limited data that were available on COVID-19 infection in pregnancy indicated largely mild disease and good treatment outcomes with infections in the third trimester [1]. However, recent reports have demonstrated that COVID-19 infection during pregnancy is associated with increased risks of hospitalization, admission to an intensive care unit (ICU), and management with mechanical ventilation, but not with death [2] . Nevertheless, maternal deaths due to COVID-19 have been reported in the second or third trimesters [3] . Moreover, pregnant women may be at an increased risk of illness from COVID-19 compared with J o u r n a l P r e -p r o o f nonpregnant women. Preexisting comorbidities, high maternal age, and high body mass index seem to be risk factors for severe COVID-19. Rates of preterm birth are higher in pregnant women with COVID-19 than in pregnant women without the disease [4]. Pregnant women with COVID-19 who experience respiratory failure present multiple management challenges. Here, the case of a COVID-19-positive, 29-year-old primiparous Japanese woman at 34 weeks of gestation presenting with severe respiratory compromise is presented. She experienced critical respiratory failure. Her clinical course and medical management are described. A 29-year-old primiparous woman (body mass index 27.5 kg/m 2 ) was referred to university hospital at 34 weeks and 2 days of gestation because of a positive throat swab for severe acute respiratory syndrome coronavirus 2 on quantitative real-time polymerase chain reaction. The patient had a 4-day history of fever and dyspnea. On admission, her body temperature was 39.0°C and saturation O 2 (SpO 2 ) was 95% (room air). A chest computed tomography (CT) scan revealed bilateral multifocal ground-glass opacities with partial consolidation, corresponding to COVID-19 pneumonia ( Figure 1) . Laboratory data showed a white blood cell (WBC) count of 8800/μL, lymphocyte 12.4%, C-reactive protein (CRP) 3.54 mg/L, D-dimer 2.3 μg/mL (<1.0 μg/mL), and IL-6 487 pg/ml (<4.0). Maternal laboratory values during the course of treatment are presented in Table 1 , and the timeline of her treatment is detailed in Figure 2 . Ciclesonide inhalation 400 μg/day, dexamethasone 6.6 g/day, heparin sodium 10,000 U/day, and sulbactam/ampicillin 6 g/day were initiated. On the second day after J o u r n a l P r e -p r o o f Journal Pre-proof admission, the patient continued to have high fever with chill and shivers, and her dyspnea worsened. SpO 2 was 95% with a 1 L/min oxygen flow through nasal cannula. Remdesivir 200 mg/day and tocilizumab 8 mg/kg were administered on the next day. On the fourth day after admission (at 34 weeks and 5 days of gestation), her respiratory condition rapidly worsened, and the SpO 2 was 94%-95% with a 3-4 L/min oxygen mask. Laboratory data showed WBC count of 9000/μl, lymphocyte 11.5%, CRP 10.41 mg/L, and D-dimer 1.5 μg/mL, and chest CT findings showed rapid deterioration On admission, our patient seemed to have mild to moderate disease; however, 3 days later, her disease progressed rapidly, and the respiratory failure was considered to require ventilator or ECMO management. The rationale for early delivery, at 34 weeks of gestation, by cesarean section included the opportunity to safely transport the patient to the operating room and the assumption that delivery could decrease maternal oxygen consumption and improve lung mechanics. In addition, delivery made it easier to manage the patient's breathing. It has been speculated that changes in cardiovascular function and immune response during pregnancy exacerbate COVID-19 infection [11] . Physiological changes during pregnancy reduce the mother's resistance to infection [12] . In addition, anatomical changes (e.g., an increase in the transverse diameter of the After cesarean section, the patient's fever quickly remitted; however, her respiratory condition deteriorated, and the pneumonia findings on chest CT worsened. Re-expansion of the lungs and increased blood volume in the reflux circulation after delivery might have contributed to the deterioration of these conditions. Accordingly, the patient was placed on mechanical ventilation in the ICU. However, the patient was no longer pregnant and she experienced successful and rapid improvement 4 days after the start of intubation. She was discharged with her baby 12 days after cesarean delivery. Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Weekly / MMWR Morb Mortal Wkly Rep Maternal death due to COVID-19 for PregCOV-19 Living Systematic Review Consotium. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis Potential Maternal and Infant Outcomes from (Wuhan) Coronavirus 2019-nCoV Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records COVID-19 in pregnancy: early lessons Clinical manifestations and outcome of SARSCoV-2 infection during pregnancy Symptoms and Critical Illness Among Obstetric Patients With Coronavirus Disease Maternal and perinatal outcomes with COVID-19: A systematic review of 108 pregnancies Goodnight WH, Soper DE. Pneumonia in pregnancy Cardio-respiratory physiological adaptation of pregnancy Handbook of Obstetric Medicine Transplacental transmission of SARS-CoV-2 infection The authors would like to thank Enago (www.enago.jp) for the English language review of this article.